The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer

Pranoto, Agung; Haryasena, Haryasena; Prihantono, Prihantono; Rahman, Septiman; Sampepajung, Daniel; Indra, Indra; Syamsu, Salman Ardi; Sampepajung, Elridho; Nelwan, Berti

doi:10.3233/bd-219010

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2018, the GLOBOCAN database recorded 2 million new cases of BC worldwide, and 626,000 fatalities caused by this disease [ 1 ]. In Indonesia, BC is also the most frequent cancer among women [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study

Amiruddin

Massi

Islam

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background Around 70% of breast cancers (BCs) are estrogen receptor-α (ERα)-positive. Adjuvant endocrine therapy is used to reduce estrogen levels and inhibit signal transduction through the ER. The anti-estrogen drugs that are most commonly used in endocrine therapy belong to the selective ER modulator (SERM) class and include tamoxifen. Although it has been used for three decades in cases of early-stage and ERα-positive BC, resistance to tamoxifen is a common problem. microRNAs (miRNAs) have a potential role in demonstrating BC resistance to tamoxifen therapy. Hence, there is a need to investigate the expression of miRNA-221 (miR-221) in luminal-subtype BC patients receiving tamoxifen therapy. Methods This case-control study investigated luminal-subtype BC patients who had undergone endocrine therapy for at least 1 year. The case group comprised patients with local or metastatic recurrence, and the control group comprised patients without local or metastatic recurrence. Results There was a significant difference in miR-221 expression ( p = 0.005) between the case and control groups. There were no significant differences between the groups that were positive and negative for the progesterone receptor (PR) ( p = 0.25), had high and low marker of proliferation Ki-67 levels ( p = 0.60), were positive and negative for lymphovascular invasion ( p = 0.14), and had stage 2 and stage 3 cancer ( p = 0.25). Conclusion miR-221 expression was higher in tamoxifen-resistant BC cases. miR-221 is a potential biomarker of tamoxifen resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study

Amiruddin

Massi

Islam

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…The molecular subtype classifications used were triple-negative, HER2, luminal B, and luminal A [5][6][7].…”

Section: The Molecular Subtype Of Breast Cancermentioning

confidence: 99%

The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer

Amansyah,

Prihantono,

Hamid

et al. 2024

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients. METHODS: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26. RESULTS: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022). CONCLUSIONS: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.

show abstract

“…Programmed death ligand 1 ( PD-L1 ), also known as CD274, is activated by its receptor, programmed death 1 (PD-1, CD279), which is found on the cell surface of T cells, B cells, and dendritic cells [ 8 , 9 ]. PD-L1 may react directly to integrin receptors, activating intracellular signaling pathways such as the AKT/GSK3 pathway, increasing cells’ propensity to migrate and invade [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Masadah,

Ikram,

Riadi

et al. 2024

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

Introduction: Ovarian cancer is a primary cause of cancer-related death in women. At the time of diagnosis, the majority of ovarian malignancies had metastasized. It is believed that cancer stem cells (CSCs) and immune evasion play a crucial role in the metastatic process. The objective of this study was to describe the expression profiles of cluster of differentiation (CD)133, CD47 , and programmed death ligand 1 ( PD-L1 ) in high-grade serous ovarian cancer (HGSC) as commonly utilized markers for CSCs and immune evasion. Material and methods: Using an immunohistochemical procedure, 51 HGSC tissue samples were stained with anti- CD133 , anti- CD47 , and anti- PDL1 antibodies. The samples contained 31 HGSC with metastases and 20 HGSC absent metastases. The expression of CD133, CD47 , and PD-L1 was compared between groups. Results: Strong expression of CD133 and CD47 was seen in 52% and 66% of tissue samples, respectively. Twenty of the thirty-one patients with metastases had a significant level of CD133 expression, with a p-value of 0.039. CD47 expression was increased in 26 of 31 samples with metastatic disease. A 62.7 percent of samples were negative for PD-L1 expression, significantly inversely correlated with HGSC metastatic disease (p=0.023). Although there was no significant association between CD133, CD47, or PD-L1 expression and age, Tumor Infiltrating Lymphocytes demonstrated a significantly varied relationship. Conclusion: Our findings suggested that expression of CD133, CD47 , and PD-L1 may have dynamically increased as the primary lesion progressed to the metastatic lesion, implying that these proteins may be involved in the progression of high-grade serous ovarian cancer from the primary to the metastatic stage.

show abstract

The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer

Cited by 6 publications

References 20 publications

microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study

microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study

The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Contact Info

Product

Resources

About